Biovica International AB (publ)

Biovica International AB (publ) operates as a biotechnology enterprise, concentrating on the development and market introduction of sophisticated blood-based biomarker tests. These diagnostic solutions aim to enhance the tracking and prediction of cancer treatment efficacy across Sweden and globally, with a significant focus on breast cancer. A key offering is DiviTum, a biomarker assay engineered to measure the activity levels of the enzyme thymidine kinase-1 within blood serum or cell cultures. The company's clientele includes oncology research centers, pharmaceutical corporations, and various collaborative organizations. Established in 2008, Biovica's main office is situated in Uppsala, Sweden.